Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene

J Cheung, Y T Mak, S Papaioannou, B A J Evans, I Fogelman and G Hampson

Department of Chemical Pathology, St Thomas’ Hospital, London, UK
1Department of Orthodontics and Paediatric Dentistry, Guy’s Hospital, London, UK
2Child Health, University Hospital of Wales, Cardiff, UK
3Nuclear Medicine, Guy’s Hospital, London, UK

(Requests for offprints should be addressed to G Hampson; Email: geeta.hampson@kcl.ac.uk)

Abstract

Oestrogen inhibits bone resorption, at least in part, by regulating the production of several cytokines, including interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) by cells of the osteoblastic lineage. The selective oestrogen receptor modulator raloxifene (RAL) acts on bone in a similar manner to oestrogen, although the mechanisms of action of RAL on osteoblasts still remain unclear. We investigated and compared the effects of 17-β oestradiol (E2) and RAL on the regulation of IL-6, IL-1, RANKL and OPG in vitro in primary human osteoblastic (HOB) cells and in an immortalised clonal human bone marrow stromal cell line (HCC1) with osteoblastic characteristics.

We tested E2 and RAL at concentrations ranging from 10^{-12} to 10^{-6} M. IL-6, IL-1α and IL-1β, OPG and RANKL were measured by ELISA. RANKL and OPG mRNA steady state level was assessed by quantitative PCR analysis. Both E2 and RAL led to a significant reduction in IL-6 production in the HOB cells, although the effect was more marked with E2 (P<0.05). IL-1α and IL-1β also decreased significantly following treatment with E2 and RAL in the HCC1 cells (E2 (10^{-8}, 10^{-7} and 10^{-6} M), % reduction (means ± s.e.m.) compared with vehicle-treated cells – IL-1α: 84 ± 7.4, 70.8 ± 2.9*, 78.2 ± 4.8*; IL-1β: 79 ± 10, 72.8 ± 8.2*, 66.6 ± 2.8*; RAL (10^{-8}, 10^{-7} and 10^{-6} M) – IL-1α: 72.4 ± 5*, 79 ± 5.2*, 102 ± 7.7; IL-1β: 67.9 ± 3.2*, 69 ± 2.5*, 73.8 ± 6.2*; *P<0.05). OPG protein concentration decreased significantly in a dose-dependent manner following treatment with E2 and RAL (% reduction E2 (10^{-8}, 10^{-7} and 10^{-6} M) – HOB: 72.5 ± 8.4*, 80 ± 6.7*, 62.8 ± 8.9*; HCC1: 109 ± 4, 98.8 ± 6, 54.5 ± 3.4*; RAL (10^{-8}, 10^{-7} and 10^{-6} M) – HOB: 81.5 ± 5.5*, 62.7 ± 7.4*, 55.2 ± 10.9*; HCC1: 92.7 ± 7.4, 67 ± 12.2*, 39 ± 4.5*; *P<0.05). In the HCC1 cells, RANKL protein did not change significantly following E2. In contrast, a significant reduction in RANKL was seen with RAL at 10^{-7} and 10^{-6} M (66 ± 6.4% and 74 ± 3% respectively). There was no change in OPG mRNA expression following E2 or RAL in the HCC1 cells, although in the HOB cells we observed a significant reduction in OPG mRNA. RANKL mRNA decreased significantly in the HCC1 cells following RAL (10^{-8}, 10^{-7} and 10^{-6} M) treatment (% change from controls: 52 ± 2*, 62 ± 1*, 53 ± 5.8*; *P<0.05). Similar results were seen in the HOB cells with RAL at 10^{-7} M (RANKL mRNA: 72 ± 5.5, P<0.05). In addition, there was a significant decrease in the RANKL/OPG ratio after RAL at 10^{-6} M (HOB: 65.6 ± 5.5*, HCC1: 56.9 ± 20*; *P<0.05). RANKL/OPG ratio did not change significantly in the HCC1 cells following E2. However, in contrast to RAL, we observed an increase in the RANKL/OPG ratio in the HOB cells following treatment with E2. In conclusion, the study shows that RAL and E2 have divergent cell-specific effects on the regulation of cytokines. The data also suggest that, in contrast to E2, RAL may exert its anti-resorptive actions, at least in part, via the RANKL/OPG pathway. Further in vivo studies are required to confirm this.


Introduction

Oestrogen prevents bone loss by inhibiting bone resorption (Compston 2001). Although some of the anti-resorptive effects of oestrogen are via direct actions on osteoclasts and haematopoietic cells, the steroid hormone has also been shown to have indirect effects by regulating osteoblasts and bone marrow stromal cells (Oursler 1998).
Oestrogen has thus been shown to modulate osteoclastic bone resorption, at least in part, by regulating the production of several pro-resorptive paracrine factors such as interleukin-6 (IL-6), IL-1β and tumour necrosis factor-α (TNF-α) by cells of the osteoblastic lineage (Spelsberg et al. 1999). More recently, a cell-surface member of the TNF ligand family termed receptor activator of nuclear factor κB ligand (RANKL) (Yasuda et al. 1998), its receptor (RANK) (Hsu et al. 1999) and osteoprotegerin (OPG) (Simonet et al. 1997) have been shown to be central in both osteoclast development and activity. OPG acts as a decoy receptor for RANKL, thus preventing it from binding to and activating RANK on the osteoclast surface. Both OPG and RANKL are expressed by osteoblastic cells and bone marrow stromal cells (Hofbauer et al. 2001). It is now thought that the final step in the osteoclast regulatory pathway may be determined by the relative ratio of RANKL to OPG (Hofbauer et al. 1999). The RANKL/OPG system may thus be an important paracrine mediator of the anti-resorptive effects of oestrogen. Indeed, recent in vitro studies in human osteoblastic (HOB) and murine stromal cells have shown that oestrogen stimulates OPG production (Saika et al. 2001).

Selective oestrogen receptor modulators (SERMs) such as raloxifene (RAL) are now being used as anti-resorptive agents for the prevention and treatment of osteoporosis (Etinger et al. 1999). Although an oestrogen agonist on bone, the mechanism of action of RAL on osteoblasts at the tissue level is still unclear. SERMs interact with the oestrogen receptor and, in those tissues where they have agonistic actions, it is thought that they modulate gene transcription in a manner similar to oestrogen, albeit at a different site to the classic oestrogen response element (Compston 2001). The effects of RAL on the regulation of the cytokines detailed above by HOB cells remain to be established. In order to explore further the mechanisms of action of RAL on bone, we examined and compared the effects of RAL and 17-β oestradiol (E2) on the regulation of the bone-resorbing cytokines such as IL-6, IL-1 and RANKL and the anti-resorptive factor OPG in primary HOB cells as well as in an immortalised human bone marrow stromal cell line (HCC1) representative of an early osteoblastic cell line (Harrison 1996, Davies et al. 2002, Ogston et al. 2002).

Materials and Methods

Cell culture

We studied the osteosarcoma-derived human cell line, SaOS-2, an immortalised human bone marrow stromal cell line with osteoblastic characteristics (HCC1) (Harrison 1996, Davies et al. 2002, Ogston et al. 2002) and primary HOB cells.

SaOS-2 cells The SaOS-2 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Paisley, Scotland, UK), supplemented with 5% foetal calf serum (FCS, Invitrogen), penicillin (100 IU/ml), streptomycin (100 µg/ml) and amphotericin B (2·5 µg/ml) in 24-well plates (Gibco BRL) at 37 °C in a humidified 5% CO2 incubator. The cells were seeded at a density of 5 × 104 per cm2 and grown to confluence.

HCC1 cells The HCC1 cells were grown to confluence in minimum essential medium (MEM, Gibco BRL) containing 10% FCS, penicillin (100 IU/ml), streptomycin (100 µg/ml) and amphotericin B (2·5 µg/ml) in 24-well plates as described above. They were not grown in differentiating culture conditions. The HCC1 cell line was derived from a bone marrow aspirate from a 45-year-old male donor undergoing spinal fusion. The immortalised cell line was established following insertion of the SV40 large T and has been shown to express several osteoblastic markers such as alkaline phosphatase, osteocalcin and the PTH/PTH-rp receptor (Harrison 1996, Davies et al. 2002, Ogston et al. 2002).

Primary HOB cells The HOB cells were obtained from trabecular bone obtained at operation from four different subjects (two males, two females). Ethical approval had been obtained from the local Research Ethics Committee. The cells were grown from the bone explants in α-MEM and 10% FCS as previously described (Cheng et al. 1994). At confluence, they were sub-cultured in 24-well plates. Only cells of the first four passages were used in the experiments. The HOB cells were shown to express several osteoblastic markers including alkaline phosphatase, type 1 collagen, CBFA1 and osteocalcin mRNA. The HOB and HCC1 cells were also shown to express the oestrogen receptor (ERα and ERβ) by RT-PCR and confirmed by sequencing, as shown in Fig. 1a and b. Primer sequences for ERα were as previously described (Morishita et al. 1999). RT-PCR was also carried out to assess the expression of the bone-specific ERβ isofrom (Poolla et al. 2002) using the following primer sequences: Forward primer: 5'-ACCTTACCTGTAAACAGGA CA-3' and reverse primer 5'-CTGTGACCAGAGG TACAT-3'. The expected PCR product size was 459 bp. ERβ mRNA expression could be detected in both the HCC1 and HOB cells, although the expression was lower and more variable than ERα.

Cell treatment with E2 and RAL

At confluence, the cells were washed with PBS and changed to serum-free DMEM.

For the experiments designed to study the effects of E2 and RAL at supra-physiological concentrations of 10-8, 10-7 and 10-6 M on IL-6 production, the Sa-OS-2, HCC1 and HOB cells were incubated in serum-free DMEM
with either vehicle or E2 or RAL for 72 h. Lower concentrations of E2 and RAL ranging from 10^{-12} to 10^{-9} M were also tested. The conditioned medium was then collected and the supernatant stored at -20 °C until analysis. For the studies on OPG secretion, the HCC1 and HOB cells were grown in serum-free DMEM for 24 h. The medium was then changed and the cells were treated with either vehicle or E2 or RAL for 24 h in fresh serum-free DMEM. The culture medium was then harvested and stored at -20 °C until analysis. For the measurement of RANKL, IL-1α and IL-1β, the HCC1 cells were grown in serum-free DMEM with either vehicle, E2 or RAL for 72 h. The cells were then trypsinised and suspended in 0.5 ml PBS. The cell suspension was sonicated for 120 s and centrifuged at 4000 g for 3 min. RANKL, IL-1α and IL-1β were measured in the supernatant. All experiments were carried out at least two or three times in triplicates.

Measurement of IL-6, IL-1α, IL-1β, OPG and RANKL
IL-6, IL-1α and IL-1β were measured by an ELISA using kits from R & D Systems (Abington, UK). OPG was also determined by ELISA. The assay consists of a monoclonal mouse anti-human OPG antibody as a capture antibody in combination with a biotinylated goat anti-human OPG affinity-purified polyclonal detection antibody (R & D Systems). Recombinant human OPG with concentrations ranging from 0.01 to 50 ng/ml were used as standards. Uncomplexed RANKL was measured using the human soluble RANKL ELISA from Biomedica (A-1210 Vienna, Divischgasse, Austria). A series of standards ranging from 0 to 50 pmol/l and supernatant from the cell sonicates were assayed in duplicate. PBS was used as the 0 standard. All values were corrected for protein. Protein concentrations were determined by the method of Bradford (Bradford 1976) on the cell lysates.

Indirect immunolocalisation of OPG and RANKL
The expression of OPG and RANKL protein was assessed qualitatively by immunolocalisation. The HCC1 and HOB cells were grown in Lab-Tek chamber slides (Nunc, Nottingham, UK). Following fixation in 4% paraformaldehyde (PFA) for 10 min, they were washed three times in Tris–HCl buffer (pH 7.6). Non-specific activity was blocked with 20% normal rabbit serum for 30 min. The cells were incubated with primary goat anti-human polyclonal antibodies against either OPG or RANKL (Santa Cruz Biotechnology Inc, Santa Cruz, USA) for 1 h at 1:200 dilution. The slides were examined by bright field.
microscopy and photographed on Kodak 64K film. To check specificity of staining, negative control slides were processed without either primary antibodies, or secondary antibody, or incubated with goat immunoglobulins.

**OPG and RANKL mRNA expression**

Total cellular RNA was isolated from the HCC1 and HOB cells following incubation in serum-free DMEM with vehicle or E₂ or RAL for 24 h. RNA was extracted using the Trizol reagent (Invitrogen) and purified according to the manufacturer’s instructions. cDNA was synthesised from 4µg of total RNA in a 40 µl reaction containing random hexanucleotides and Moloney murine leukaemia virus reverse transcriptase (Invitrogen).

**Real-time quantitative PCR assay for OPG and RANKL mRNA expression**

Real-time quantitative PCR analysis was done using a 5700 Sequence Detector (PE Applied Biosystems, Foster City, CA, USA), which is a combined thermal cycler and fluorescence detector with the ability to monitor the progress of individual PCR reactions optically during amplification. Amplification reactions were set up in 25 µl reaction volumes containing amplification primers and SYBR Green PCR Master Mix (PE Applied Biosystems). A 1 µl volume of cDNA was used in each amplification reaction. Preliminary experiments were carried out for primer concentration optimisation. Primer sequences are detailed below and were derived using Primer Express Software (PE Applied Biosystems). Sequence data were obtained from the GenBank Sequence Database (accession numbers U94332 (OPG), AF019047 (RANKL)).

**Primer sequences**

**Beta-actin**  
Forward primer: 5’-CCCAGCCATGTACGTTGCTA  
Reverse primer: 5’-AGGGGATACCCCCCTCGTAGATG  

**OPG**  
Forward primer: 5’-CGTCAAGCGAGGTGCAATC  
Reverse primer: 5’-CCAGCTTTGCAACCACTCAA  

**RANKL**  
Forward primer: 5’-TCGTTGGATCAGACGACATCA  
Reverse primer: 5’-TATGGGAACCAGATGGGATGTGTC

Amplifications were performed in 96-well reaction plates designed to prevent light scattering (PE Applied Biosystems). Calibration curves were run in parallel in triplicates for each analysis. Each sample was analysed six times during each experiment. The experiments were carried out at least twice on each cell line. Amplification data were analysed using the Sequence Detector System Software (PE Applied Biosystems). The results were normalised to β-actin and expressed as percentage of controls.

**Statistical analyses**

The statistical significances of differences between the control and treated cells were determined by Student’s t-test. The critical value for significance was P<0·05. Values are given as means ± s.e.m.

**Results**

**The effect of E₂ (10⁻⁸–10⁻⁶ M) and RAL (10⁻⁸–10⁻⁶ M) on IL-6 secretion**

In the SaOS-2 cells, IL-6 production was significantly reduced following treatment with E₂ at all concentrations tested. In contrast, RAL led to a significant decrease in IL-6 at a concentration of 10⁻⁷ M only (72·2 ± 5·8% of vehicle-treated controls, P<0·01). In the HOB cells, IL-6 was significantly reduced in the presence of E₂ (10⁻⁸, 10⁻⁷, 10⁻⁶ M) compared with controls (87 ± 3·6%, 61·7 ± 7·8%, 63·4 ± 6·9%, P<0·01). RAL led to a reduction in IL-6 in the HOB cells at concentrations of 10⁻⁷ and 10⁻⁶ M only (82·9 ± 3·9% and 84·6 ± 4·2%, P<0·05). At all concentrations tested, the addition of E₂ to the HOB cells resulted in a more profound inhibition of IL-6 production than RA (P<0·05). In the HCC1 cells, we observed a reduction in IL-6 production after treatment with RAL only at concentrations of 10⁻⁸ and 10⁻⁷ M (78 ± 4·0% and 67·7 ± 2·4%, P<0·05). The results are shown in Fig. 2. In the HOB cells, IL-6 production was stimulated (five- to tenfold) in response to lipopolysaccharide (LPS 10 mg/ml). Co-treatment with E₂ (10⁻⁸ and 10⁻⁷ M) attenuated the stimulated IL-6 production of controls (77 ± 5·3% and 82 ± 3·2%, P<0·05). Co-treatment with RAL (10⁻⁸ M) also resulted in a reduction in IL-6 of controls (87 ± 4·0%, P<0·05). There was no significant change in IL-6 following treatment with E₂ or RAL at lower concentrations (10⁻¹²–10⁻⁹ M).

**Intracellular IL-1α, IL-1β and RANKL**

IL-1α and IL-1β could not be detected in the conditioned medium in any of the cell lines by the specific ELISA. Intracellular IL-1α and IL-1β could be detected and were well above the detection limit of the assay in the HCC1 cells only. A significant reduction in IL-1α was seen following treatment with E₂ (10⁻⁷, 10⁻⁶ M) (70·8 ± 2·9% and 78·2 ± 4·8% of vehicle-treated controls, P<0·01). Similar results were observed with RAL at 10⁻⁸ and
10^{-7} M, as shown in Fig. 3. IL-1β was also significantly reduced after treatment with E2 (10^{-7}, 10^{-6} M) and RAL (10^{-8}–10^{-6} M) (Fig. 3). No changes were observed at lower E2 and RAL concentrations (10^{-12}–10^{-9} M). RANKL could only be detected in the HCC1 cells following sonication. The mean ± S.E.M. in the vehicle-treated cells was 6.05 ± 0.4 pmol/l, which was at the lower end of the assay range. Values expressed as a percentage of control for E2 (10^{-8} M, 10^{-7} M) were 106 ± 30% and 100 ± 4% respectively. A small reduction in RANKL was seen following treatment with E2 (10^{-8} M, 10^{-7} M) (114 ± 14%). Treatment with RAL (10^{-7}, 10^{-6} M) led to a significant reduction in RANKL compared with vehicle-treated cells (66 ± 6.4% and 74 ± 3%, *P<0.05). RANKL could not be detected in the HOB cell sonicates.

**OPG protein secretion**

OPG protein concentration in the conditioned medium decreased significantly in a dose-dependent fashion in both the HOB and HCC1 cells following treatment with E2 (10^{-8}–10^{-6} M) and RAL (10^{-8}–10^{-6} M) at supra-physiological concentrations only. However the decrease was less than that observed in dexamethasone-treated cells (10^{-9}–10^{-7} M). The results are shown in Fig. 4. No changes were observed at lower E2 and RAL concentrations (10^{-12}–10^{-9} M).

**OPG and RANKL protein expression by immunolocalisation**

Pink staining for OPG and RANKL was detected in both the HCC1 and HOB cells. Basal expression of OPG was higher than RANKL, as shown in Fig. 5. Basal RANKL protein expression in the cells was too low to allow accurate semi-quantitative assessment (by cell counting) of RANKL protein expression following treatment with E2 and RAL.

**Real-time PCR quantitative analysis of OPG and RANKL mRNA**

OPG and RANKL mRNA expression normalised to actin and the RANKL/OPG ratio was expressed as percentages.
of controls in the HOB and HCC1 cells and is shown in Fig. 6. There was no change in OPG mRNA steady state levels in the HCC1 cells following treatment with E₂ and RAL (10⁻⁸–10⁻⁶ M). The results for E₂ and RAL (10⁻⁶ M) are shown in Fig. 6. In contrast, we observed a significant reduction in RANKL mRNA expression at RAL concentrations of 10⁻⁷ and 10⁻⁶ M and RANKL/OPG ratio at RAL (10⁻⁶ M) in the HCC1 cells. The mean ± S.E.M. percentage reduction in RANKL mRNA expression and RANKL/OPG ratio in the HCC1 cells following treatment with RAL (10⁻⁶ M) was 64.9 ± 5.8% and 56.9 ± 20% compared with controls (P < 0.01) (Fig. 6). RANKL mRNA expression was significantly lower following treatment with RAL (10⁻⁶ M) compared with E₂ (10⁻⁶ M) (P < 0.05) in the HCC1 cells. No significant reduction in RANKL/OPG ratio was seen following E₂ (10⁻⁶ M) treatment in the HCC1 cells. RAL (10⁻⁶ M) treatment also led to a reduction in RANKL mRNA and the RANKL/OPG ratio in the HOB cells (72 ± 5.5% and 65.6 ± 5.0%, P < 0.01). There was a significant reduction in OPG mRNA expression following E₂ in the HOB cells. In contrast, there was no significant change in either RANKL mRNA or the RANKL/OPG ratio in the HOB cells versus control following E₂ treatment, although the results were different compared with RAL (Fig. 6).

**Discussion**

In the present study we have shown that both E₂ and RAL treatment down-regulate the production of bone-resorbing cytokines IL-6, IL-1α and IL-1β by HOB cells. In addition, we also observed an inhibition in OPG protein production/secretion by E₂ and RAL. RANKL protein, mRNA expression and the RANKL/OPG mRNA ratio were more profoundly decreased following treatment with RAL compared with E₂, suggesting that RAL and E₂ may have different effects on RANKL expression. The results also indicate that the effects of RAL on HOB cells may favour a reduction in bone resorption through modulation of the RANKL/OPG system.

In the studies reported here, treatment with E₂ at physiological and supra-physiological doses resulted in a reproducible reduction in IL-6 production by HOB cells. Previous studies of the effect of E₂ on IL-6 production in osteoblasts have been equivocal (Kassem et al. 1996). This has been attributed, in part, in some human in vitro systems to the heterogeneity of the osteoblastic cell systems and to low ER expression. In this study, in addition to primary osteoblastic cultures, a homogeneous clonal cell line was used (Davies et al. 2002). Steady state levels of ERα mRNA expression were found to be similar in both culture systems. In the HOB cells, E₂ inhibited basal as well as stimulated IL-6 production. This effect was more marked than with RAL. In contrast, however, in the clonal osteoblastic cell line, HCC1, only RAL had an inhibitory effect on IL-6 production. One explanation for this finding is the origin of the cell line, which was obtained from the bone marrow aspirate of an adult male subject (Ogston et al. 2002). It is unlikely that the differences in the effects of E₂ and RAL on IL-6 production in this cell line are due to differences in the number of ERαs, as we observed no differences in the mRNA steady state levels between the HOB and HCC1 cells. However, it is plausible that our findings may be due to differential activation of ER subtypes by E₂ and RAL. This differential effect of RAL and E₂ on IL-6 production has also been reported (Taranta et al. 2002) in murine osteoblasts, although in contrast to our study they observed a reduction in IL-6 at lower concentrations of RAL. Other bone-resorbing cytokines also mediate part of the
oestrogenic action on bone and this includes IL-1α and IL-1β. Constitutive levels of IL-1α and IL-1β were low in the HOB cells. The pattern of reductions in the pro-resorbing cytokines IL-1α and IL-1β was similar following treatment of the HCC1 cells by either E₂ or RAL. The inhibitory effect of E₂ on IL-1 production could, at least in part, explain how E₂ down-regulates osteoclast activity, as previously reported (Pacifici 1998). Our data also confirm this effect with regards to RAL.

It is now thought that the ratio of RANKL/OPG determines osteoclast differentiation and activation, and that these two downstream factors serve as the final effectors in the modulation of bone resorption (Hofbauer et al. 2000). The RANKL/OPG system is also believed to be a mediator of E₂ anti-resorptive actions. Several investigators have shown that E₂ increases the production of OPG (Hofbauer et al. 1999, Saika et al. 2001). In our study, we observe a reduction in OPG in the primary HOB cultures and in the clonal cell line HCC1 following treatment with E₂ at concentrations ranging from 10⁻⁸ to 10⁻⁶ M. This effect was also seen with RAL. Changes in OPG of this order of magnitude (30–40%) have previously been shown to be of physiological and clinical significance in in vivo studies (Lindberg et al. 2001, Khosla et al. 2002). One explanation for the lack of OPG stimulation observed in our study is the lower ER numbers in our cell culture model, as in the studies mentioned above the extent of OPG protein secretion was dependent on ER receptor.
numbers and maximal stimulation was shown in cells over-expressing ERα. Indeed, the magnitude of OPG induction by E2 was shown to be relatively small in primary osteoblast cultures and in untransfected ST-2 cells, a mouse bone marrow stromal cell line. Secondly, our results could be attributed to differences in culture conditions. Thirdly, differences in ERβ expression in our cell culture system may account for our findings. Indeed, Saika et al. (2001) have recently shown a negative regulation by the E2–ERβ complex on OPG expression. It is also plausible that a reduction in the upstream cytokines such as IL-6 and IL-1 leads to inhibition of OPG secretion as these cytokines have been shown to stimulate OPG production in vitro (Hofbauer et al. 1998, Vidal et al. 1998b), although data regarding IL-6 remain conflicting (Brindstrøm et al. 1998). These results would be compatible with the hypothesis that E2’s effects on OPG may be indirect (Riggs et al. 2002) and are mediated at least in part by the modulation of other cytokines, as previously suggested for TGF-β (Oursler et al. 1991, Hughes et al. 1997). This interaction between various cytokines has previously been reported to explain the anti-resorptive effects of E2. Increased bone marrow levels of IL-1 in ovariectomised mice have been shown to be, at least in part, a result of increased TNF-α production (Cenci et al. 2000). Fourthly, the inhibitory effect of E2 on OPG is supported by the findings of Yano et al. (1999), who showed an increase in OPG in post-menopausal women that was postulated to be a compensatory response to increases in bone resorption seen in this population. Our in vitro findings of a reduction in OPG following E2 and RAL treatment would be consistent with a reduction in bone turnover and slowing of bone remodelling. Indeed, a recent in vivo study (Lindberg et al. 2001) has shown the decrease in bone turnover following E2 treatment in orchidectomised mice to be associated with a 30% decrease in OPG mRNA expression as confirmed in the present study in the HOB cells, although the authors did not investigate OPG protein expression. Our study also suggests that the mechanisms of inhibition of OPG secretion by E2 and RAL are cell specific and in the case of RAL occur at the post-transcriptional level as, in contrast to Saika et al. (2001) and Lindberg et al. (2001), we observed no change in OPG mRNA expression. Similar findings of a lack of effect of E2 and RAL on OPG mRNA expression have been reported (Vidal et al. 1998a, Taranta et al. 2002). The divergence of OPG regulation would imply that RAL may have an inhibitory effect, directly or indirectly at the

Figure 5 OPG and RANKL protein expression by immunolocalisation in the HCC1 and HOB cells. (A) OPG expression in the HCC1 cells. (B) RANKL expression in the HCC1 cells. (C) OPG expression in the HOB cells. (D) RANKL expression in the HOB cells.
post-transcriptional level, on the assembly of the protein and/or secretion of the homodimeric form. This remains to be investigated.

RANKL expression at the mRNA and protein level was much lower than OPG in the HOB and HCC1 cells. The number of HOB and HCC1 cells that stained positive for RANKL was small. RAL led to a significant reduction in RANKL mRNA in both the HCC1 and HOB cell lines. In addition, RANKL protein expression was also seen to decrease with RAL in the HCC1 cultures. In contrast, RANKL mRNA and protein expression did not change with E2 in the HCC1 cells and HOB cells. This has previously been reported (Saika et al. 2001, Taranta et al. 2002), although Lindberg et al. (2001) reported an increase in RANKL mRNA expression following E2 treatment. Our data further confirm the differences in the mechanisms of action of RAL and E2 at the molecular level (Lonard & Smith 2002). The differential effects between E2 and SERMs regulation of gene transcription may be attributed, at least partly, to their different interaction with ERα and ERβ. RAL activates transcription with both ERα and ERβ. In contrast, oestrogen interacts with ERα to activate transcription, whereas with ERβ it inhibits transcription (Compston 2001). Another explanation is ligand-specific conformational changes in the ligand-binding domain of the ER which can affect gene transcription, as previously shown in the case of RAL and tamoxifen (Brzozowski et al. 1997, Shiau et al. 1998). Other cell-type and promoter-specific differences in coregulator recruitment may also explain the divergent effects of E2 and RAL (Shang & Brown 2002).

Because the interaction between RANKL and RANK depends on the balance between RANKL and OPG, its decoy receptor, we looked at the RANKL/OPG mRNA ratio. We observed a significant reduction in the RANKL/OPG mRNA ratio by RAL which would favour reduction in bone resorption. Our data therefore show that RAL may act via the RANKL/OPG system, at least in part, for its anti-resorptive effect. In contrast, with E2 we observed no change in the RANKL/OPG mRNA ratio.

**Figure 6** mRNA expression of OPG and RANKL and the OPG/RANKL ratio expressed as a percentage of control (vehicle-treated cells) following treatment with E2 and RAL (10^{-6} M) in the HCC1 cells (a) and in the HOB cells (b). The results are the means ± S.E.M. of three different experiments carried out in triplicate. *P<0.05 compared with control, #P<0.05 compared with E2-treated cells.
ratio in the HCC1 cells and in the HOB cells we saw an increase in the RANKL/OPG mRNA ratio compared with RAL, again demonstrating the differential effects of the two ligands on different cell cultures, as discussed above. Our results would indicate a relative increase in the RANKL/OPG ratio with E2, as we saw a reduction in OPG but no change in RANKL. Other additional regulatory pathways may therefore be involved in E2’s anti-resorptive effects and may involve, in part, modulation of RANK expression by osteoclasts (Shevde et al. 2000).

In conclusion, although E2 and RAL share common pathways in the regulation of bone resorption by HOB cells, this study shows that the two agents also have divergent cell-specific effects, particularly on the RANKL/OPG pathway. Further studies are needed to investigate and compare the effects of these two agents at the molecular level on the multiple regulatory factors involved in bone remodelling.

Acknowledgements

We would like to thank Eli Lilly & Co. for supplying the RAL compound and Dr B Ashton, Department of Rheumatology, Robert Jones and Agnes Hunt, Orthopaedic Hospital, Oswestry, UK for kindly donating the HCC1 cell line to us.

References


Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2 and cytokines. Biochemical and Biophysical Research Communications 250 776–781.


Saika M, Inoue D, Kido S & Matsumoto T 2001 17\(\beta\)-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-\(\alpha\). *Endocrinology* 142 2205–2212.
Vidal ON, Sjögren K, Eriksson BI, Ljunggren O & Ohlsson C 1998b Osteoprotegerin mRNA is increased by interleukin-6 in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. *Biochemical and Biophysical Research Communications* 248 696–700.

Received 29 January 2003
Accepted 13 February 2003